Trial Information
Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma
Inclusion Criteria:
- FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium
- Post menopausal status must be demonstrated
- Signed informed consent
Exclusion Criteria:
- FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the
endometrium
- Younger than 40 or postmenopausal status not established
- Pregnant or breastfeeding
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Changes in Ki67 expression after about 3 weeks of Letrozole treatment for patients with endometrial cancer
Outcome Time Frame:
At time of consent until hysterectomy (generally about 3 weeks)
Safety Issue:
No
Principal Investigator
Lloyd H. Smith, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of California, Davis
Authority:
United States: Institutional Review Board
Study ID:
200917341
NCT ID:
NCT00997373
Start Date:
October 2009
Completion Date:
August 2012
Related Keywords:
- Endometrial Carcinoma
- Endometrial Cancer
- Endometrial Carcinoma
- Aromatase Inhibitor
- Letrozole
- Femara
- Carcinoma
- Endometrial Neoplasms
- Adenoma
Name | Location |
|---|
| University of California, Davis |
Sacramento, California 95818 |
| University of California Davis |
Sacramento, California 95817 |
